Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $243.47 +2.51%
EPS Growth %: +174.9%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
CRMT, More
EPS Growth %: +174.9%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $8.13, $2.20 better than the analyst estimate of $5.93. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees Q4 2025 revenue of $4.175-4.275 billion, versus the consensus of $4.221 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Midera Food Processing and Centrus Energy to join S&P SmallCap 600
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
